Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Efficacy and Safety of B-Cell Maturation Antigen (BCMA) Antibody-Drug Conjugates (ADC) in Development against Cancer: A Systematic Review.

Oncology research·2026
Same author

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.

British journal of pharmacology·2025
Same author

A novel therapeutic strategy for osteosarcoma using anti-GD2 ADC and EZH2 inhibitor.

Biomarker research·2025
Same author

Ionic liquids as stabilisers of therapeutic protein formulations: a review of insulin and monoclonal antibodies.

Biophysical reviews·2025
Same author

Current Protein Conjugation Strategies and Pioneering Anti-Cancer Applications.

Discovery medicine·2023
Same author

A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer.

Pharmaceutics·2023

Related Experiment Video

Updated: Mar 7, 2026

Bridging the Bio-Electronic Interface with Biofabrication
16:38

Bridging the Bio-Electronic Interface with Biofabrication

Published on: June 6, 2012

17.4K

Biobetters From an Integrated Computational/Experimental Approach.

Serdar Kuyucak1, Veysel Kayser2

  • 1School of Physics, University of Sydney, NSW 2006, Australia.

Computational and Structural Biotechnology Journal
|February 10, 2017
PubMed
Summary
This summary is machine-generated.

Computational methods accelerate the development of biobetters, which are improved protein-based drugs. Accurate computational predictions reduce experimental testing for novel therapeutics like antibodies and toxin analogs.

Keywords:
DockingFree energy perturbationMolecular dynamicsPotential of mean forceRational drug design

More Related Videos

A Versatile Automated Platform for Micro-scale Cell Stimulation Experiments
12:21

A Versatile Automated Platform for Micro-scale Cell Stimulation Experiments

Published on: August 6, 2013

11.1K
Multi-analyte Biochip MAB Based on All-solid-state Ion-selective Electrodes ASSISE for Physiological Research
08:03

Multi-analyte Biochip MAB Based on All-solid-state Ion-selective Electrodes ASSISE for Physiological Research

Published on: April 18, 2013

17.9K

Related Experiment Videos

Last Updated: Mar 7, 2026

Bridging the Bio-Electronic Interface with Biofabrication
16:38

Bridging the Bio-Electronic Interface with Biofabrication

Published on: June 6, 2012

17.4K
A Versatile Automated Platform for Micro-scale Cell Stimulation Experiments
12:21

A Versatile Automated Platform for Micro-scale Cell Stimulation Experiments

Published on: August 6, 2013

11.1K
Multi-analyte Biochip MAB Based on All-solid-state Ion-selective Electrodes ASSISE for Physiological Research
08:03

Multi-analyte Biochip MAB Based on All-solid-state Ion-selective Electrodes ASSISE for Physiological Research

Published on: April 18, 2013

17.9K

Area of Science:

  • Biotechnology
  • Computational Biology
  • Drug Design

Background:

  • Biobetters are modified peptide or protein therapeutics with enhanced properties like target affinity and stability.
  • Computational methods are crucial for predicting successful modifications, reducing experimental workload.
  • Therapeutic areas include autoimmune diseases and cancers, utilizing toxin peptide analogs and monoclonal antibodies.

Purpose of the Study:

  • To discuss computational and experimental methods in biobetter design.
  • To highlight the inverse relationship between computational accuracy and experimental effort.
  • To provide examples of biobetter design strategies for specific therapeutic applications.

Main Methods:

  • Review of computational approaches for predicting drug properties.
  • Analysis of experimental validation techniques for biobetters.
  • Case studies on designing selective toxin peptide analogs and monoclonal antibodies.

Main Results:

  • Accurate computational predictions significantly decrease the number of necessary experiments.
  • Computational tools enable the rational design of biobetters with improved efficacy and safety profiles.
  • The integration of computational and experimental methods is key to efficient biobetter development.

Conclusions:

  • Computational methods are indispensable for the efficient design and development of biobetters.
  • Optimizing computational predictions minimizes experimental costs and timelines.
  • Biobetters represent a significant advancement in therapeutic agent development, particularly for complex diseases.